What is HC Wainwright’s Estimate for VTYX FY2029 Earnings?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) – Analysts at HC Wainwright issued their FY2029 earnings estimates for Ventyx Biosciences in a research report issued on Tuesday, January 14th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($1.34) for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Ventyx Biosciences’ current full-year earnings is ($2.09) per share.

Separately, Oppenheimer restated an “outperform” rating and set a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Ventyx Biosciences Trading Up 1.0 %

NASDAQ:VTYX opened at $1.96 on Thursday. Ventyx Biosciences has a 1 year low of $1.67 and a 1 year high of $11.48. The firm’s fifty day simple moving average is $2.28 and its 200 day simple moving average is $2.28.

Insider Transactions at Ventyx Biosciences

In other Ventyx Biosciences news, insider John Nuss sold 13,161 shares of the stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $2.26, for a total value of $29,743.86. Following the completion of the sale, the insider now directly owns 485,701 shares of the company’s stock, valued at $1,097,684.26. This represents a 2.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Raju Mohan acquired 261,752 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were bought at an average price of $2.01 per share, for a total transaction of $526,121.52. Following the acquisition, the chief executive officer now owns 2,175,028 shares in the company, valued at approximately $4,371,806.28. This trade represents a 13.68 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 630,000 shares of company stock worth $1,262,415. Insiders own 18.18% of the company’s stock.

Hedge Funds Weigh In On Ventyx Biosciences

Several large investors have recently added to or reduced their stakes in VTYX. JPMorgan Chase & Co. increased its position in shares of Ventyx Biosciences by 2.0% during the third quarter. JPMorgan Chase & Co. now owns 1,007,519 shares of the company’s stock valued at $2,196,000 after purchasing an additional 20,236 shares during the period. Barclays PLC boosted its stake in Ventyx Biosciences by 273.1% during the third quarter. Barclays PLC now owns 80,295 shares of the company’s stock worth $175,000 after buying an additional 58,776 shares in the last quarter. Geode Capital Management LLC boosted its stake in Ventyx Biosciences by 5.9% during the third quarter. Geode Capital Management LLC now owns 1,391,702 shares of the company’s stock worth $3,034,000 after buying an additional 77,350 shares in the last quarter. XTX Topco Ltd bought a new stake in Ventyx Biosciences in the 3rd quarter valued at $246,000. Finally, State Street Corp raised its stake in shares of Ventyx Biosciences by 0.8% in the 3rd quarter. State Street Corp now owns 1,187,650 shares of the company’s stock valued at $2,589,000 after buying an additional 9,783 shares in the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.